Directorate Change

By

Regulatory News | 04 Jan, 2019

Updated : 11:00

RNS Number : 2332M
Reckitt Benckiser Group PLC
04 January 2019
 

 

 

 

4 January 2019

 

 

 

RECKITT BENCKISER GROUP PLC

('RB' or 'the Company')

 

 

RB announces that, as part of its succession planning for the Board and Audit Committee, the Board has asked Warren Tucker to remain on the Board as a Non-executive Director and as a member of the Audit Committee for an additional 12 months from the Company's 2019 AGM.  Warren had been intending to retire and step down from the Board at the 2019 AGM, having joined the Board in 2010.  He has now agreed to stand for re-election at the 2019 AGM and, subject to re-election, to extend his tenure on the RB Board until the AGM to be held in May 2020.

 

Contact:

Rupert Bondy

Company Secretary

Reckitt Benckiser Group plc

01753 217800

 

103-105 Bath Road, Slough SL1 3UH

Registered in England and Wales, No. 6270876 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

About RB:
 

RB is the global leading consumer health, hygiene and home company. Driven by a purpose of providing innovative solutions for healthier lives and happier homes, RB has operations in over 60 countries.  From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, its global brands help people live healthier, happier lives.

 

RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.

 

RB's unique culture is at the heart of its success.  Its drive to achieve, passion to outperform and commitment to quality and scientific excellence is manifested in the work of over 40,000 employees worldwide. 

 

For more information visit www.rb.com 

 

*RB is the trading name of the Reckitt Benckiser group of companies

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGUGUGUPBGUC

Last news